文献速递区域麻醉与超声疼痛医学

静脉与神经周围地塞米松作为外周神经阻滞佐剂的剂量-效应关系:系统综述与基于模型的网状Meta分析

Dose-response relationships of intravenous and perineural dexamethasone as adjuvants to peripheral nerve blocks: a systematic review and model-based network meta-analysis.
PubMed 文献 · Br J Anaesth · 2024-01-27

该系统综述与基于模型的网状Meta分析纳入118项随机对照研究(9284例患者),评估静脉或神经周围地塞米松作为单侧外周神经阻滞佐剂的剂量-效应关系。偏倚校正后,地塞米松使镇痛持续时间最大增加1.7倍(95%CrI 1.4-1.9),神经周围与静脉途径无差异。试验模拟显示,神经周围4 mg地塞米松将长效局麻药平均镇痛持续时间从11.1 h延长至16.5 h,并减半术后恶心呕吐发生率;静脉8 mg地塞米松效果相似。

要点

  • 静脉地塞米松作为外周神经阻滞佐剂的有效性与神经周围途径相当,但效力较低,需更高剂量。
  • 偏倚校正后地塞米松延长镇痛持续时间最大达1.7倍,两途径间无差异。
  • 神经周围4 mg地塞米松延长镇痛并减半术后恶心呕吐,静脉8 mg效果相似。

核心结论

  • 静脉地塞米松作为外周神经阻滞佐剂在延长镇痛持续时间方面与神经周围地塞米松同样有效,但效力较低,需要更高剂量。

研究设计与样本

  • 系统综述与基于最大效应(Emax)模型的网状Meta分析,检索截至2023年10月,纳入118项随机对照研究(9284例患者),其中35项使用静脉地塞米松、106项使用神经周围地塞米松,剂量范围1-16 mg。

主要发现

  • 偏倚校正后,地塞米松使镇痛持续时间最大增加1.7倍(95%CrI 1.4-1.9),神经周围与静脉途径间无差异。
  • 试验模拟显示,神经周围4 mg地塞米松将长效局麻药平均镇痛持续时间从11.1 h(95%CrI 9.4-13.1)延长至16.5 h(95%CrI 14.0-19.3),并将术后恶心呕吐发生率减半。
  • 静脉8 mg地塞米松观察到相似幅度的效应。
  • 偏倚不明确或高风险的 study 高估了地塞米松的效应。

关键数值与推荐

  • 地塞米松剂量范围1-16 mg。
  • 偏倚校正后镇痛持续时间最大增加1.7倍(95%CrI 1.4-1.9)。
  • 神经周围4 mg地塞米松:镇痛持续时间从11.1 h(95%CrI 9.4-13.1)延长至16.5 h(95%CrI 14.0-19.3),术后恶心呕吐发生率减半。
  • 静脉8 mg地塞米松效应幅度与神经周围4 mg相似。

临床怎么用

  • 静脉地塞米松可作为外周神经阻滞佐剂替代神经周围途径,但需使用更高剂量(如静脉8 mg相当于神经周围4 mg的效应幅度)。
  • 神经周围4 mg地塞米松可延长长效局麻药镇痛持续时间并减少术后恶心呕吐。

局限性

  • 剂量-效应关系为观察性性质。
  • 纳入研究质量有限。
  • 偏倚不明确或高风险的 study 高估了地塞米松效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Superiority of perineural over intravenous dexamethasone at extending nerve block analgesia has been suggested but without considering the dose-response relationships for each route of administration. METHODS: Randomised control studies that evaluated intravenous or perineural dexamethasone as an adjuvant to unilateral peripheral nerve blocks in adults were searched up to October 2023 in MEDLINE, Central, Google Scholar, and reference lists of previous systematic reviews. The Cochrane Risk-of-Bias tool was used. A maximum effect (Emax) model-based network meta-analysis was undertaken to evaluate the dose-response relationships of dexamethasone. RESULTS: A total of 118 studies were selected (9284 patients; 35 with intravenous dexamethasone; 106 with perineural dexamethasone; dose range 1-16 mg). Studies with unclear or high risk of bias overestimated the effect of dexamethasone. Bias-corrected estimates indicated a maximum fold increase in analgesia duration of 1.7 (95% credible interval (CrI) 1.4-1.9) with dexamethasone, with no difference between perineural and intravenous routes. Trial simulations indicated that 4 mg of perineural dexamethasone increased the mean duration of analgesia for long-acting local anaesthetics from 11.1 h (95% CrI 9.4-13.1) to 16.5 h (95% CrI 14.0-19.3) and halved the rate of postoperative nausea and vomiting. A similar magnitude of effect was observed with 8 mg of intravenous dexamethasone. CONCLUSIONS: Used as an adjuvant for peripheral nerve block, intravenous dexamethasone can be as effective as perineural dexamethasone in prolonging analgesic duration, but is less potent, hence requiring higher doses. The evidence is limited because of the observational nature of the dose-response relationships and the quality of the included studies. SYSTEMATIC REVIEW PROTOCOL: PROSPERO CRD42020141689.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Zufferey PJ, Chaux R, Lachaud PA, et al. Dose-response relationships of intravenous and perineural dexamethasone as adjuvants to peripheral nerve blocks: a systematic review and model-based network meta-analysis. Br J Anaesth. 2024. PMID: 38281844. doi:10.1016/j.bja.2023.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。